years of experience
APIs scaled up across 10 therapeutic categories
Drug Master Files (DMFs) worldwide
active US DMFs
API manufacturing capacity
of revenue from exports
R&D employees approximately 300
Much of the credit for our success also goes to our strong, well-balanced teams across functions, who worked closely to serve customer needs in an extraordinary year.
The strategic direction we have followed in recent years, with an increased focus on growing our capabilities and our Custom Manufacturing Solutions (CMS) business without compromising on our Generic Drugs Substances (GDS) strategy, is driving our sustained performance.
We are investing in building stronger capabilities in R&D, as we have identified that as a strategic priority for driving the next phase of growth.